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As causative agents of duck viral hepatitis, duck hepatitis A virus type 1 (DHAV-1) and
type 3 (DHAV-3) causes significant economic losses in the duck industry. However, a
licensed commercial vaccine that simultaneously controls both pathogens is currently
unavailable. Here, we generated duck enteritis virus recombinants (rC-KCE-2VP1)
containing both VP1 from DHAV-1 (VP1/DHAV-1) and VP1 from DHAV-3 (VP1/DHAV-
3) between UL27 and UL26. A self-cleaving 2A-element of FMDV was inserted between
the two different types of VP1, allowing production of both proteins from a single open
reading frame. Immunofluorescence and Western blot analysis results demonstrated
that both VP1 proteins were robustly expressed in rC-KCE-2VP1-infected chicken
embryo fibroblasts. Ducks that received a single dose of rC-KCE-2VP1 showed
potent humoral and cellular immune responses and were completely protected against
challenges of both pathogenic DHAV-1 and DHAV-3 strains. The protection was rapid,
achieved as early as 3 days after vaccination. Moreover, viral replication was fully blocked
in vaccinated ducks as early as 1 week post-vaccination. These results demonstrated,
for the first time, that recombinant rC-KCE-2VP1 is potential fast-acting vaccine against
DHAV-1 and DHAV-3.
Keywords: duck hepatitis A virus type 1, duck hepatitis A virus type 3, duck enteritis virus, VP1, 2A-element,
vaccine
INTRODUCTION
Duck virus hepatitis (DVH) is an acute, highly contagious, and rapidly fatal disease of young
ducklings usually less than 4 weeks of age. This disease is characterized primarily by ecchymotic
hemorrhage and liver necrosis. DVH is mainly caused by duck hepatitis A virus (DHAV). DHAV,
which belongs to the family Picornaviridae and genus Avihepatovirus, was first described in the
USA in 1949. DHAV strains are categorized into three different serotypes: the traditional serotype
1 (DHAV-1; Levine and Fabricant, 1950; Asplin, 1965; Kim et al., 2006; Ding and Zhang, 2007), a
serotype only reported in Taiwan (DHAV-2; Tseng and Tsai, 2007), and a novel serotype isolated in
China and South Korea (DHAV-3; Fu et al., 2008; Xu et al., 2012). No cross-neutralization reaction
between DHAV-1 and DHAV-2 (Tseng et al., 2007) and limited cross-neutralization reaction
between DHAV-1 and DHAV-3 (Kim et al., 2007) have been reported. In mainland China, DVH is
primarily caused by DHAV-1 and DHAV-3, and infection by DHAV-2 has not been documented to
date (Kim et al., 2007; Fu et al., 2008).
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As a member of Picornaviridae, DHAV is a small, non-
enveloped virus with a single-stranded, positive-sense RNA
genome approximately 7800 nucleotides in length. The whole
open reading frame (ORF) encodes three mature structural
proteins, namely, capsid proteins 0 (VP0), 1 (VP1), and 3 (VP3).
The ORF also encodes nine non-structural proteins (A1–2A2–
2A3–2B–2C–3A–3B–3C–3D). Among these proteins, the major
surface protein VP1 is the principal antigenic determinant that
plays an essential role in pathogenicity, evolution, and virulence
(Jin et al., 2008; Liu et al., 2008; Li C. et al., 2013; Zhang et al.,
2015). Therefore, VP1 is a potential target for vaccine and drug
development.
Co-infection with DHAV-1 and DHAV-3 has recently become
increasingly frequent in domestic ducks, resulting in major
economic losses to the duck industry in China and Korea
(Chen et al., 2013; Chen L. et al., 2014; Soliman et al., 2015).
However, no commercial DHAV vaccine is presently available to
simultaneously control both DHAV-1 and DHAV-3. Obviously,
alternative strategies for developing vaccines to prevent co-
infections by DHAV-1 and DHAV-3 are urgently needed.
Duck viral enteritis, which is caused by infection with the
virulent duck enteritis virus (DEV), is a highly serious infectious
disease in duck (Li Y. et al., 2009). Vaccination combined with
strict biosecurity practices has been the recommended approach
for controlling DEV infection. Attenuated DEV of the C-KCE
strain from embryonated chicken egg has been routinely used
as live vaccine in ducks for over half a century without safety
concerns for humans and any other animals (Liu et al., 2011;
Wu et al., 2012). Additionally, C-KCE vector offers the advantage
of efficiently generating both humoral and cellular immune
responses (Shawky and Schat, 2002). More importantly, C-KCE
is stable, efficacious, and cost effective to produce. Additionally,
the vector overcomes pre-existing antibodies (Liu et al., 2011).
In recent years, the C-KCE vaccine strain has been developed
as a vector for expressing foreign antigens for vaccine purposes.
Previously, our group successfully generated C-KCE strain-based
recombinant viruses delivering the hemagglutinin (HA) gene of
avian influenza virus H5N1 as a bivalent vaccine for protecting of
ducks against H5N1 and DEV challenges (Zou et al., 2015). The
robust protection afforded by the C-KCE-H5HA vaccine against
a lethal H5N1 challenge raises the possibility that the C-KCE
vector will prove useful not only for avian influenza virus but also
for other viruses in ducks. In the present study, to explore this
hypothesis, we further engineered the C-KCE vector to express
two different types of VP1 from DHAV-1 and DHAV-3. We also
evaluated the ability of the recombinant C-KCE to protect ducks
from DHAV-1 and DHAV-3 challenge.
MATERIALS AND METHODS
Ethics Statements
All of the animal experiments were approved by the Research
Ethics Committee, Huazhong Agricultural University, Hubei,
China (HZAUMO2015-0015). All the animal experiments were
carried out in accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals from Research
Ethics Committee, Huazhong Agricultural University, Hubei,
China.
Virus Strains and Cells
The attenuated DEV C-KCE vaccine strain, obtained from the
China Institute of Veterinary Drugs Control, was propagated
and titrated in chicken embryo fibroblasts cells (CEFs) cultured
in M199 medium (Gibco) supplemented with 10% fetal bovine
serum (FBS) and 1% antibiotics.
DHAV-1 (JX-1) (GenBank accession number: EF093502.1)
and DHAV-3 (Hubei 1302) (GenBank accession number:
KJ744260.1) were propagated in the allantoic cavities of 10-day-
old specific-pathogen-free (SPF) embryonated duck egg. The
allantoic fluids were collected and stored at−80◦C.
Generating the Recombinant Virus
rC-KCE-2VP1
We previously established a system to regenerate C-KCE
by a combined bacterial artificial chromosome (BAC) and
mating-assisted genetically integrated cloning (MAGIC) strategy
(Figure 1A). This strategy allowed us to achieve stable insertion
of the HA gene from H5N1 between the UL26 and UL27 genes of
C-KCE without altering the replication and immunogenicity of
the parental virus (Zou et al., 2015).
To construct the rC-KCE-2VP1, the gene fragment
(VP1/DHAV-1 + 2A + VP1/DHAV-3) was synthesized by
Sangon Biotech Life Science Products and Services as outlined
in Supplementary Figure 1. Subsequently, the fragment was
cloned into the BamH I and EcoR I sites present in pRThGA1
to generate the donor vector plasmid pRThGA1-2VP1, whereas
the self-cleaving 2A peptide of FMDV acted as a labile linker
between the two genes VP1/DHAV-1 and VP1/DHAV-2. Details
of the methods used for MAGIC-mediated recombineering are
provided elsewhere (Zou et al., 2015). A rC-KCE-2VP1 construct
without the BAC vector was also generated as described
previously (Wang and Osterrieder, 2011).
Confirmation of Expression of Two
Different Types of VP1 in CEFs Infected
with rC-KCE-2VP1
Expression of two different types of VP1 protein in rC-
KCE-2VP1 was evaluated by immunofluorescence (IFA) and
Western blot. For IFA, the CEFs grown on coverslips in six-
well plates were infected at an MOI of 1 with rC-KCE-2VP1
or C-KCE. Monoclonal antibodies (mAb) against VP1/DHAV-
1 and VP1/DHAV-3 (previously prepared in our laboratory)
were used as primary antibodies. Details of the methods used
for produce mAb against VP1/DHAV-1 and VP1/DHAV-3 are
provided elsewhere (Yang et al., 2011). Briefly, adult female
BALB/c mice were injected with purified VP1/DHAV-1 or
VP1/DHAV-3 protein with adjuvant. The secondary antibodies
were fluorescein isothiocyanate-labeled goat anti-rabbit IgGs
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). The CEFs
nuclei were then stained with 4′-6-diamidino-2-phenylindole
(DAPI). The cells were observed under a fluorescence microscope
(Carl Zeiss, Germany). For Western blot analysis, VP1 expression
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FIGURE 1 | Insertion of foreign genes into the C-KCE genome. (A) Full-length C-KCE clone harboring mini-F plasmid with the red fluorescent protein as a
selection marker. (B) Generation a duck enteritis virus (DEV) recombinants (rC-KCE-2VP1) containing two types of VP1/DHAV (duck hepatitis A virus)-1 and
VP1/DHAV-3 between UL27 and UL26 with a self-cleaving 2A-element.
was analyzed in CEFs in six-well plates infected with rC-KCE-
2VP1 and C-KCE at an MOI of 1. mAb against VP1/DHAV-1
and VP1/DHAV-3, mAb (the same mAb against VP1/DHAV-1)
against 2VP1, Polyclonal antibodies (pAb) against gB (previously
prepared in our laboratory), and mAb against GAPDH (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) for the control
were used as primary antibodies. Goat horseradish peroxidase
(HRP)-conjugated anti-rabbit or anti-mouse IgGs were used
as secondary antibodies. The bands were visualized using ECL
detection reagents (Thermo, USA) in accordance with the
manufacturer’s instructions.
Animal Experiments
Specific-pathogen-free ducks were obtained from the Harbin
Veterinary Research Institute, China. A total of 387 1-day-
old SPF ducks were adopted for our studies. Three animal
experiments were conducted to evaluate the immunogenicity and
protective efficacy of the rC-KCE-2VP1 vaccine against DHAV-1
and DHAV-3 challenges.
Experiment 1
To test the serological responses against VP1/DHAV-1 and
VP1/DHAV-3 in ducks immunized with rC-KCE-2VP1, we
randomly divided the ducks into three groups (five per group),
each group receiving one immunization subcutaneously with 105
PFU (recommended dose for DEV vaccine in the field) of rC-
KCE-2VP1, C-KCE, or PBS as negative control. Serum samples
were then collected from all the groups to evaluate serological
responses at 3 days, 1, 2, 3, 4, and 5 weeks post-vaccination (pv).
Experiment 2
To evaluate the level of clinical protection provided by rC-KCE-
2VP1 against DHAV-1 and DHAV-3, 312 ducks were randomly
divided into 24 groups (13 per group). A total of eight groups of
ducks were inoculated subcutaneously with 105 PFU of rC-KCE-
2VP1, and 16 groups were inoculated with 105 PFU of C-KCE
or PBS as negative control. The ducks were then intramuscularly
challenged with 100 LD50 of DHAV-1 or DHAV-3 at 3 days,
1, 2, or 4 weeks pv. Three ducks in each DHAV-1/DHAV-3
virus-challenged group were then humanely sacrificed on day
2 post-challenge (pc), and duck organs, including liver, lung,
spleen, kidney, and brain, were collected to determine viral titers.
Experiment 3
To measure the T-cell responses in the spleens of vaccinated
ducks, 12 groups of ducks (five per group) were subcutaneously
inoculated with rC-KCE-2VP1 (105 PFU), C-KCE (105 PFU), or
PBS (control). At 3 days, 1, 2, 4, and 5 weeks pv, the ducks were
sacrificed humanely. Their spleens were harvested to screen the
cellular immune responses.
Interferon-Gamma (IFN-γ) ELISpot Assay
T-cell responses were determined using an IFN-γ ELISpot assay
(Li Z. et al., 2013). Briefly, duck spleens were homogenized and
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washed with Hank’s Balanced Salt Solution. Gey solution was
then added to remove the red blood cells. Splenocytes purified
from ducks in Complete Tumor Medium were added into a
96-well plate (seeded at 2 × 105 cells/well) pretreated with
70% ethanol and coated with anti-duck IFN-γ mAb. Cells were
restimulated with synthetic peptides derived from VP1/DHAV-
1 or VP1/DHAV-3 as a specific antigens, respectively. The
cultures were incubated under 37◦C and 5% CO2 for 48 h and
conducted in accordance with the manufacturer’s protocol (TSZ,
USA). Spots were counted using an AID ViruSpot Reader (Cell
Technology, Inc.). Results are presented as the mean number of
cytokine-secreting cells subtracted by the mean number of mock
stimulation per 106 splenocytes.
Serological Analysis of Duck Serum
Duck sera were harvested at different time points to evaluate
the antibody levels by indirect enzyme-linked immunosorbent
assay (ELISA) and neutralization test. For indirect ELISA, ELISA
plates (Corning Costar) were briefly coated with purified His-
tagged VP1/DHAV-1 or VP1/DHAV-3 proteins and incubated
overnight at 4◦C. After blocking, the plates were incubated
with duplicate twofold serial dilutions of test sera for 1 h at
37◦C. HRP-conjugated goat anti-rabbit IgG was used at 1:2000
dilution to detect bound antibodies for 1 h at 37◦C. The
wells were then rinsed with PBST and incubated with TMB.
Substrate development was stopped by adding 2 mM sulfuric
acid. Optical density (OD) was measured at 450 nm using a
TECAN microtiter plate reader. For the neutralization test, all
serum samples were mixed and inactivated at 56◦C for 30 min.
The neutralization test was then performed using 9-day-old SPF
duck embryonated eggs as described previously (Song et al.,
2014).
RT-PCR Assay for the Detection of Viral
Loads
Virus titers in heart, spleen, liver, kidney, and brain were
determined by using a one-step real-time TaqMan RT-PCR assay
(Yang et al., 2008). The set of primers and probes used in this
research have been previously validated (Lin et al., 2016). The
primers and TaqMan probe for DHAV-1 were DHAV-1F, DHAV-
1R, and Probe 1. The primers and TaqMan probe for DHAV-3
were DHAV-3F, DHAV-3R, and Probe 2. DHAV-1TF, DHAV-
1TR, DHAV-3TF, and DHAV-3TR (Supplementary Table 1) were
designed to amplify the fragments of two standard templates.
The fragments were then cloned into pGEM-T Easy vector in
accordance with the instructions of the manufacturer (Promega).
One-step, real-time TaqMan RT-PCR assays were carried out on
an Applied Biosystems 7500 Fast real-time PCR system (Life
Technologies, Carlsbad, CA, USA).
Statistical Analysis
All experiments were reproducible and performed in triplicate.
Statistical analyses were conducted by a one-way ANOVA test to
compare the data of the difference groups using GraphPad Prism
version 5.0 (GraphPad Software, La Jolla, CA, USA). p-values of
<0.05 were considered statistically significant.
RESULTS
Generation and Characterization of
Recombinant C-KCE Containing the
VP1/DHAV-1 and VP1/DHAV-3
A recombinant C-KCE carrying the HA gene of the influenza
A/duck/Hubei/xn/2007 (H5N1) virus was previously generated
by a combined BAC and MAGIC strategy (Zou et al., 2015). By
using the same strategy, here we generated a recombinant C-KCE
virus carrying the VP1/DHAV-1 and VP1/DHAV-3 inserted into
the UL27 and UL26 gene junction, under the control of chicken
β-actin promoter and cytomegalovirus immediate enhancer. We
designated the resulting recombinant C-KCE virus as rC-KCE-
2VP1 (Figure 1B).
Expression of the inserted VP1 gene in the rC-KCE-2VP1-
infected cells was determined by Western blot and IFA. Western
blot analysis was performed on the whole-cell extract of rC-KCE-
2VP1-infected CEFs. Protein bands of approximately 26 kDa
(molecular mass of the VP1 protein of DHAV) were clearly
visible in the rC-KCE-2VP1-infected cell extract, demonstrating
that VP1/DHAV-1 and VP1/DHAV-3 were efficiently expressed
(Figure 2A). Moreover, VP1/DHAV-1 protein was expressed at
levels similar to that of VP1/DHAV-3. Meanwhile, the cleavage
efficiency of the 2A element was incomplete (Figure 2A),
which was consistent with a previous study in which the
2A element was found to mediate cleavage at about 90%
efficiency (Li J. et al., 2009). As expected, no specific bands were
observed in either mock (PBS)-infected or C-KCE-infected cell
lysates.
The results of IFA matched well with those of Western
blot analysis. Upon examining the rC-KCE-2VP1-infected
CEFs stained with a mixture of anti-VP1/DHAV-1 and anti-
VP1/DHAV-3 antibodies, both red and green fluorescence signals
were observed by fluorescence microscopy. Notably, the red
and green fluorescence signals co-localized to the same CEFs
(Figure 2B). However, cells infected with PBS and C-KCE showed
no red and green fluorescence (Figure 2B). Thus, these results
confirm that both VP1/DHAV-1 and VP1/DHAV-3 proteins were
robustly expressed with a C-KCE vector using the 2A-element.
Induction of Antibody Response in
rC-KCE-2VP1-Vaccinated Ducks
To evaluate the immunogenicity of the recombinant rC-KCE-
2VP1 vaccine, total anti-VP1/DHAV-1 and anti-VP1/DHAV-
3 antibody responses were determined by an indirect ELISA.
As shown in Figure 3A, antibody levels of the C-KCE and
PBS-inoculated groups were lower and considered negative. In
contrast to the antibody level in the control group, the earliest
time point of detection of anti-VP1/DHAV-1 antibody in the
rC-KCE-2VP1-vaccinated groups was week 2. In particular, the
mean antibody level started to increase in week 3 but peaked
with statistically significant difference compared to weeks 2 and
3 in week 4. However, the antibody level began to decline in
week 5 (Figure 3A). The anti-VP1/DHAV-3 antibody responses
were consistent with those observed for anti-VP1/DHAV-1
(Figure 3B).
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FIGURE 2 | Detection of VP1/DHAV-1 and VP1/DHAV-3 expression by rC-KCE-2VP1 in infected chicken embryo fibroblasts cells (CEFs). (A) Detection
of VP1/DHAV-1 and VP1/DHAV-3 protein expression in rC-KCE-2VP1-infected CEFs by Western blot. (B) Confirmation of the expression of VP1/DHAV-1 and
VP1/DHAV-3 protein in rC-KCE-2VP1-infected CEFs by using immunofluorescence. CEFs infected with C-KCE or mock-infected CEFs were used as controls.
FIGURE 3 | Induction of anti-VP1 antibodies by rC-KCE-2VP1 in ducks. Groups of five ducks were inoculated subcutaneously with 105 PFU of rC-KCE-2VP1,
C-KCE, or PBS (negative control). Sera were obtained at the indicated time points and pooled for detection of anti-VP1 antibodies by indirect ELISA. Serum samples
were diluted in fetal bovine serum (FBS) at 1:50 for antibody detection. Each sample was independently tested twice. The result was obtained from mean ELISA
absorbance values of three sera in each group. (A) Antibody responses were then assessed against the VP1/DHAV-1. (B) Antibody responses were assessed
against the VP1/DHAV-3. The dashed line shows the detection limit for a positive response. Data are shown as the means ± SD. ∗ P < 0.05; ∗∗ P < 0.01.
Next, serum samples were further assessed using the
neutralization test assay to detect the presence of neutralizing
antibodies, a marker of immunogenicity, against both
VP1/DHAV-1 and VP1/DHAV-3. No detectable neutralizing
antibodies were observed against VP1/DHAV-1 and VP1/DHAV-
3 tested in ducks that received mock vaccination during the
entire experimental period (data not shown). On the other
hand, all the ducks vaccinated with the rC-KCE-2VP1 vaccine
seroconverted at 2 weeks pv, with mean anti-VP1/DHAV-1
neutralizing antibody titers of 2 log2. The neutralizing antibody
titers reached up to 3 log2 at 2 weeks pv and reached a peak of
5 log2 at 4 weeks. However, the titers gradually declined since
5 weeks pv (Figure 4). In addition, the mean NA levels against
DHAV-1 and DHAV-3 was not statistically significant. Overall,
these results revealed that ducks vaccinated with rC-KCE-2VP1
could induce humoral immune responses simultaneously against
DHAV-1 and DHAV-3.
Cellular Response to rC-KCE-2VP1 Viral
Vaccination
Interferon-Gamma ELISpot assays were performed to evaluate
whether rC-KCE-2VP1 can prime cellular immune responses.
As expected, ducks that received the rC-KCE-2VP1 vaccine
showed statistically significant increase in the number of IFN-
γ-secreting cells in the spleen at each of the pv time points
(3 days, 1, 2, 4, and 5 weeks), regardless of whether the spleen cells
were stimulated with synthetic VP1/DHAV-1 or VP1/DHAV-3
peptide (Figure 5). Interestingly, the number of IFN-γ-secreting
splenocytes stimulated with synthetic VP1/DHAV-3 peptide was
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FIGURE 4 | Neutralization of antibody responses against both DHAV-1
and DHAV-3 induced by rC-KCE-2VP1 immunization in ducks. Groups
of five ducks were inoculated subcutaneously with 105 PFU of rC-KCE-2VP1,
C-KCE, or PBS (negative control). Blood samples were collected, and sera
were prepared at the indicated time points to detect the NT antibody against
DHAV-1 and DHAV-3 in nine-day-old specific-pathogen-free (SPF) duck
embryonated eggs. NT antibody titers for ducks are expressed as log2.
Dotted lines indicate the thresholds for a positive response.
significantly higher than those stimulated with VP1/DHAV-1
peptide. This was particularly notable at 4 weeks pv, when
it reached an average peak intensity of one VP1/DHAV-3-
specific T cell per 2,000 freshly isolated splenocytes (Figure 5).
However, the efficiency of protection was not different based
on subsequent challenge experiments. Thus, we speculated that
the VP1/DHAV-3 peptide was more powerful antigen than
the VP1/DHAV-1 peptide. By contrast, the mean number
of IFN-γ-secreting cells in the C-KCE and PBS-inoculated
groups that were extremely low (Figure 5) and considered
negative was limited at any of the time points. These data
indicate that rC-KCE-2VP1 immunization vigorously generated
T-cell immune responses against both VP1/DHAV-1 and
VP1/DHAV-3.
Vaccine Efficacy against Pathogenic
DHAV-1 and DHAV-3 Isolates Challenge
in Ducks
Having shown that a strong T-cell immune response was
rapidly induced after single-dose vaccination of rC-KCE-
2VP1, we next questioned whether rC-KCE-2VP1 would
confer protection against DHAV-1 and DHAV-3. Thus, the
efficacy of rC-KCE-2VP1 as a candidate vaccine was evaluated
by exposing of ducks to currently circulating isolates of
pathogenic DHAV-1 and DHAV-3 after vaccination with rC-
KCE-2VP1.
Notably, all ducks in the rC-KCE-2VP1-vaccinated that
had received DHAV-1 and DHAV-3 challenges survived at all
time points pv (Figures 6 and 7). Furthermore, no clinical
sign of disease was observed in the ducks given rC-KCE-
2VP1 at any time point pv throughout the 14-day observation
period, except for the ducks challenged on day 3 pv, which
exhibited mild and transient symptoms at the start of the
experimental period. These symptoms included slight loss
of appetite and polydipsia. Conversely, in the ducks in the
control groups C-KCE and PBS, mortality ranged from 50
to 100% (dependent on the days of ducks) with typical
clinical features of appetite loss, wasting, ataxia, wryneck, and
opisthotonus. The difference in protection efficacy between
the two groups was not statistically significant. Thus, the
rC-KCE-2VP1 candidate vaccine showed excellent protection
against currently circulating isolates of pathogenic DHAV-1 and
DHAV-3.
FIGURE 5 | rC-KCE-2VP1 viruses prime T-cell responses. Groups of five ducks were inoculated subcutaneously with 105 PFU of rC-KCE-2VP1, C-KCE, or
PBS (negative control). VP1-specific responses of splenocytes obtained at 3 days, 1, 2, 4, and 5 weeks pv as determined by Interferon-Gamma (IFN-γ)-ELISPOT
assay. (A) Splenocytes were restimulated with peptides derived from VP1/DHAV-1 as specific antigen. (B) Splenocytes were restimulated with peptides derived from
VP1/DHAV-3 as specific antigen. Data are shown as the means ± SD. ∗∗ P < 0.01; ∗∗∗ P < 0.001.
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FIGURE 6 | Conferred protection from immunization of duck with rC-KCE-2VP1 vaccine against challenge with virulent DHAV-1 challenge. Ducks were
inoculated subcutaneously with 105 PFU of rC-KCE-2VP1, 105 PFU of C-KCE, or with PBS as control then intramuscularly challenged with 100-fold DLD50 DHAV-1
at 3 days (A), 1 week (B), 2 weeks (C), or 4 weeks (D) pv, respectively. The ducks were monitored daily for 2 weeks after challenge.
Detection of Viral Load after DHAV-1 and
DHAV-3 Challenge
To determine the effect of rC-KCE-2VP1 on viral replication,
viral load in the liver, spleen, heart, kidney, and brain of ducks
in each group were examined by the one-step real-time TaqMan
RT-PCR assay. The challenge in the DHAV-1 virus was not
recovered in any organs tested in the rC-KCE-2VP1 vaccinated
ducks at weeks 1, 2, and 4 pv, and only low titers of challenge
DHAV-1 virus were detected at day 3 pv, with average viral loads
ranging from 102.68 copies/g to 103.61 copies/g (Table 1). On the
contrary, in the PBS- and C-KCE-inoculated groups, DHAV-1
replication was detected in the livers at all four time points pv
with high average viral loads ranging from 1011.23 copies/g to
109.49 copies/g. Correspondingly, the mean viral loads ranged
from 109.96 copies/g to 108.94 copies/g, 108.67 copies/g to 107.58
copies/g, 108.78 copies/g to 106.98 copies/g, and 108.15 copies/g
to 106.81 copies/g in the spleens, hearts, kidneys, and brains,
respectively (Table 1). The viral loads of DHAV-1 in the liver and
spleen were significantly higher than those in other organs, which
is consistent with previous research (Lin et al., 2016). Similar
results were observed in the DHAV-3 challenge group (Table 1).
Together, our data indicated that vaccination with rC-KCE-2VP1
completely blocked DHAV-1 and DHAV-3 replication in ducks as
early as 1 week pv.
DISCUSSION
Duck virus hepatitis, mainly caused by DHAV, is a severe
threat to the duck industry in Southeast Asia. Currently,
China and Korea are severely affected by the epidemic duck
hepatitis caused by DHAV-1 and DHAV-3. Moreover, mixed
infections caused by DHAV-1 and DHAV-3 have become
common in domestic ducks in eastern Asia. The increasing
number of DHAV outbreaks in this region highlight the urgent
need for effective control measures. Vaccination remains the
most effective method that contributes to protecting ducks
against DHAV-1 and DHAV-3 infection. Currently, modified
live virus vaccines, which are attenuated by serial passages
in chicken embryos, are available for controlling DHAV-1
infection in ducks (Woolcock and Crighton, 1979). However,
no commercial vaccine is currently approved for use in
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FIGURE 7 | Conferred protection from immunization of duck with rC-KCE-2VP1 vaccine against challenge with virulent DHAV-3 challenge. Ducks were
inoculated subcutaneously with 105 PFU of rC-KCE-2VP1, 105 PFU of C-KCE, or with PBS as control then intramuscularly challenged with 100-fold DLD50 DHAV-3
at 3 days (A), 1 week (B), 2 weeks (C), or 4 weeks (D) pv, respectively. Ducks were monitored daily for 2 weeks after challenge.
ducks against the novel DHAV-3 strain. Developing a vaccine
that simultaneously acts against both DHAV-1 and DHAV-
3 is the most economical strategy for dealing with this
crisis.
Attenuated DEV vaccine strains, including C-KCE and clone
03, have been used as vaccines over the past 50 years with proven
track records. DEV vectors fulfill several important criteria of
a promising vaccine vector in terms of efficacy, stability, and
safety. To date, DEV as a vector vaccin has been extensively
explored for use against H5N1 avian influenza virus and duck
Tembusu virus (Liu et al., 2011; Liu X. et al., 2013; Chen P.
et al., 2014; Zou et al., 2014). More importantly, DEV has
also been used as a replicating vaccine in chickens to provide
complete protection against the H5N1 influenza virus and the
avian infectious bronchitis virus (Liu J. et al., 2013; Li et al., 2016),
which greatly extends the application of DEV. However, DEV has
not been evaluated as a vaccine vector for DHAV. Therefore, we
sought to develop DEV as a vaccine vector for protection of ducks
against DHAV infections. To this end, in this study, we generated
a rC-KCE-2VP1 vector that delivered both VP1/DHAV-1 and
VP1/DHAV-3. The two different types of VP1 separated by a
2A linker were inserted into the UL27 and UL26 gene junctions
of C-KCE, which was proven not to alter the features of the
parental virus C-KCE (Zou et al., 2015). We further evaluated the
immunogenicity and protective efficacy against virulent DHAV-
1 and DHAV-3 in SPF ducks. After single dose immunization,
rC-KCE-2VP1 elicited humoral immune and cellular immune
responses to VP1/DHAV-1 and VP1/DHAV-3. As early as 3 days
pv, the ducks conferred solid protection against the DHAV-1 and
DHAV-3 challenge.
In previous studies, different genes have been delivered either
as separate ORFs (Fan et al., 1998; Szczypka et al., 1999) or
bicistronic ORFs (Levenson et al., 1998; Klein et al., 1999;
Martinez-Salas, 1999) incorporating the internal ribosome entry
site (IRES). The first approach is time-consuming and laborious,
whereas the second strategy can be limited by the dramatically
reduced expression of the gene inserted downstream of the
IRES (Roberts et al., 1998; Furler et al., 2001). Alternative
strategies are needed to overcome these obstacles. The 2A
element of FMDV, which encodes a mediator of primary
polyprotein cleavage protease, has recently been used widely
to link multiple genes in a single ORF under the control
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TABLE 1 | Replication of challenge virus in ducks.
Challenge time pv Vaccine Viral copy load in the organs in the ducks on 2 days pv (mean ± SD, log10 Copies/g)
Liver Spleen Heart Kidney Brain
DHAV-1 3 days C-KCE-2VP1 3.28 ± 0.43 3.61 ± 0.26 2.46 ± 0.37 2.27 ± 0.46 2.68 ± 0.57
C-KCE 10.26 ± 0.62 9.96 ± 0.32 7.58 ± 0.32 8.53 ± 0.43 7.56 ± 0.42
PBS 9.87 ± 0.84 10.37 ± 0.41 8.59 ± 0.54 8.78 ± 0.31 8.13 ± 0.52
1 week C-KCE-2VP1 / / / / /
C-KCE 11.23 ± 0.21 8.94 ± 0.76 8.59 ± 0.47 8.31 ± 0.39 7.94 ± 0.32
PBS 9.64 ± 0.73 10.12 ± 0.76 8.67 ± 0.24 8.37 ± 0.52 7.86 ± 0.57
2 weeks C-KCE-2VP1 / / / / /
C-KCE 9.91 ± 0.61 9.26 ± 0.49 8.31 ± 0.36 8.17 ± 0.39 8.15 ± 0.47
PBS 10.41 ± 0.27 8.89 ± 0.73 7.64 ± 0.39 6.98 ± 0.56 6.81 ± 0.83
4 weeks C-KCE-2VP1 / / / / /
C-KCE 9.49 ± 0.71 9.51 ± 0.42 7.98 ± 0.27 8.23 ± 0.31 8.11 ± 0.51
PBS 10.17 ± 0.21 9.67 ± 0.52 8.43 ± 0.19 7.87 ± 0.43 7.67 ± 0.35
DHAV-3 3 days C-KCE-2VP1 4.13 ± 0.26 3.72 ± 0.54 3.21 ± 0.33 2.47 ± 0.44 2.59 ± 0.53
C-KCE 10.16 ± 0.63 10.43 ± 0.51 8.25 ± 0.63 8.59 ± 0.31 7.73 ± 0.63
PBS 9.95 ± 0.66 10.26 ± 0.41 8.67 ± 0.31 7.74 ± 0.81 7.61 ± 0.57
1 week C-KCE-2VP1 / / / / /
C-KCE 10.29 ± 0.43 10.33 ± 0.28 7.84 ± 0.61 8.37 ± 0.52 7.86 ± 0.51
PBS 9.78 ± 0.62 9.54 ± 0.71 7.67 ± 0.72 7.82 ± 0.64 6.96 ± 0.74
2 weeks C-KCE-2VP1 / / / / /
C-KCE 9.94 ± 0.72 10.21 ± 0.42 8.13 ± 0.35 7.59 ± 0.61 6.73 ± 0.53
PBS 9.18 ± 0.52 9.71 ± 0.57 7.98 ± 0.47 8.13 ± 0.31 7.19 ± 0.62
4 weeks C-KCE-2VP1 / / / / /
C-KCE 8.89 ± 0.74 9.53 ± 0.66 7.77 ± 0.61 8.43 ± 0.39 7.96 ± 0.43
PBS 9.29 ± 0.51 9.91 ± 0.55 8.13 ± 0.43 7.97 ± 0.51 7.23 ± 0.33
DHAV (duck hepatitis A virus)-1 and DHAV-3 replication in the organs of the ducks vaccinated with C-KCE-2VP1. Groups of three ducks were inoculated subcutaneously
with 105 PFU of rC-KCE-2VP1, C-KCE, or with PBS as control. Then, the ducks were challenged with DHAV-1 or DHAV-3 intramuscularly at 3 days, 1, 2, or 4 weeks pv.
At day 2 after the challenge, the ducks were euthanized, and their organs were harvested for virus titration using a one-step, real-time TaqMan RT-PCR assay. Data are
expressed as means ± standard deviations of log10. The backslash indicates that the challenge virus was not recovered at the corresponding time point.
of a single promoter (Donnelly et al., 2001). Previously,
the FMDV 2A sequence had been successfully incorporated
in to retroviral (De Felipe and Izquierdo, 2000), lentiviral
(Chinnasamy et al., 2006), and adeno-associated (Tan et al.,
2010) vectors to construct multigene vectors. In this study,
rC-KCE-2VP1 was developed to express the different type
VP1 proteins by using 2A-element linkers between P1/DHAV-
1 and VP1/DHAV-3. We observed that the two types of VP1
genes were efficiently expressed in rC-KCE-2VP1-infected CEFs.
Moreover, the VP1/DHAV-1 protein was expressed at similar
level as the VP1/DHAV-3 protein. Thus, recombinant rC-
KCE-2VP1 was used to simultaneously express VP1/DHAV-
1 and VP1/DHAV-3 by taking advantage of the FMDV 2A
element. Utilizing 2A element, we also successfully constructed
and obtained the C-KCE co-expression of the HA of H5N1,
HA of H9N2, and E of duck Tembusu virus (data not
shown).
Of note, single doses of 105 PFU of rC-KCE-2VP1 induced
rapid protection against both lethal virus challenges by DHAV-
1 and DHAV-3 at 3 days pv. Virus replication was significantly
reduced but not totally eliminated at 3 days pv, whereas
virus replication was completely blocked at 1 week pv. This
feature makes this vaccine extremely valuable, because duck
hepatitis usually occurs as early as in less than 1-week-
old ducklings. Generally, presence of antibody against the
virus is a hallmark of protective immunity. Serological data
revealed that both anti-VP1 specific antibodies and neutralizing
antibodies were absent at 3 days pv. Similarly, a previous
study has demonstrated that ducks that received attenuated
vaccine DHAV-3 via intramuscular injection route conferred
complete protection against DHAV-3 infection at 1 days pv
(Kim et al., 2009). However, stimulating the antibody response
at this time point pv may be exceedingly early. Hence, we
can conclude that the DHAV antibody response does not
necessarily correlate with the protection. Interestingly, the
C-KCE vector itself triggers the production of interferons,
which may play a role in early control of virus infection.
However, interferon production triggered by C-KCE vector
is unlikely to contribute to the rapid protection offered by
the C-KCE-2VP1 vaccine because the control vector C-KCE
did not offer any protection. Thus, T-cell responses, which
are essential for virus clearance (Gao et al., 2006), are
required for rapid protection. Accordingly, we analyzed the
immunogenicity of rC-KCE-2VP1 and found that single dose
vaccination induced vigorously T-cell immune responses to both
VP1/DHAV-1 and VP1/DHAV-3 as early as 3 days pv. These
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results pointed that specific IFN-γ producing T cells might
contribute to the early control of DHAV infection, as early
as 3 days pv and at least until antibody responses appear, as
previously shown for avian influenza infections (Zou et al.,
2015). The mechanisms underlying for the rapid and complete
protection afforded by the rC-KCE-2VP1 vaccine in such a short
time requires further study. Further experiments are needed to
address the question.
In Summary, we have demonstrated that rC-KCE-2VP1 can be
used as a safe and effective candidate vaccine against DHAV-1 and
DHAV-3 infections. rC-KCE-2VP1 elicited potent humoral and
cellular immune responses, suggesting that C-KCE is a versatile
vaccine platform for delivering the VP1 protein. This is the
first study to show 100% protection against multiple DHAV
strains using a single-vector single-injection vaccine. As such,
rC-KCE-2VP1 is an excellent candidate trivalent live-attenuated
vaccine.
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